Molecular Mechanisms of Castrate-Resistant Prostate Cancer.

Despite newer therapies for castrate-resistant prostate cancer (CRPC), many patients do not experience a treatment response, and most eventually experience secondary resistance. Various androgen-receptor-related and alternative mechanisms of resistance in CRPC have been identified. This focus on understanding the molecular basis of therapeutic resistance, including lineage plasticity, neuroendocrine transformation, and a range of other implicated genomic alterations will hopefully inform decision-making in the care of this lethal cancer.

The Urologic clinics of North America. 2022 Oct 07 [Epub]

Srinath Kotamarti, Andrew J Armstrong, Thomas J Polascik, Judd W Moul

Division of Urology, Duke Cancer Institute, 20 Duke Medicine Circle, Durham, NC 27710, USA., Division of Urology, Duke Cancer Institute, 20 Duke Medicine Circle, Durham, NC 27710, USA; Division of Medical Oncology, Duke Cancer Institute, 20 Duke Medicine Circle, Durham, NC 27710, USA., Division of Urology, Duke Cancer Institute, 20 Duke Medicine Circle, Durham, NC 27710, USA. Electronic address: .

email news signup